Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The glucagon-like peptide 1 (GLP-1) analog ROSE-010 reduced pain during acute exacerbations of irritable bowel syndrome (IBS). Our objective was to assess effects of ROSE-010 on several gastrointestinal (GI) motor and bowel functions in constipation-predominant IBS (IBS-C). In a single-center, randomized, parallel-group, double-blind, placebo-controlled, dose-response study, we evaluated safety, pharmacodynamics, and pharmacokinetics in female patients with IBS-C. ROSE-010 (30, 100, or 300 μg sc) or matching placebo was administered once daily for 3 consecutive days and on 1 day 2–10 days later. We measured GI and colonic transit by validated scintigraphy and gastric volumes by single-photon emission computed tomography. The primary end points were half time of gastric emptying of solids, colonic transit geometric center at 24 h, and gastric accommodation volume. Analysis included intent-to-treat principle, analysis of covariance (with body mass index as covariate), and Dunnett-Hsu test for multiple comparisons. Exposure to ROSE-010 was approximately dose-proportional across the dose range tested. Demographic data in four treatment groups of female IBS-C patients (total 46) were not different. Gastric emptying was significantly retarded by 100 and 300 μg of ROSE-010. There were no significant effects of ROSE-010 on gastric volumes, small bowel or colonic transit at 24 h, or bowel functions. The 30- and 100-μg doses accelerated colonic transit at 48 h. Adverse effects were nausea ( P < 0.001 vs. placebo) and vomiting ( P = 0.008 vs. placebo). Laboratory safety results were not clinically significant. In IBS-C, ROSE-010 delayed gastric emptying of solids but did not retard colonic transit or alter gastric accommodation; the accelerated colonic transit at 48 h with 30 and 100 μg of ROSE-010 suggests potential for relief of constipation in IBS-C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Altered small bowel motility in irritable bowel syndrome is correlated with symptoms
Kellow, J. E., & Phillips, S. F. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90620-2 · Cited by 464
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Prather, C. M., Camilleri, M., Zinsmeister, A. R., McKinzie, S., & Thomforde, G. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70251-4 · Cited by 410
Self-citationGlucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246 · cited 1×
“As with other GLP-1 analogs, the repeated administration of the analog is sometimes associated with reduced prevalence of nausea and vomiting over time (40).”
BackgroundDelgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235 · cited 2×
“Changes in SPECT volumes have reproduced changes in gastric wall tone assessed with the barostat technique in response to pharmacological interventions, including GLP-1 (19).”
BackgroundMethodSelf-citationThe physiology of gastric emptying
Hellström, P. M., Grybäck, P., & Jacobsson, H. (2006) · Best Practice & Research Clinical Anaesthesiology · doi:10.1016/j.bpa.2006.02.002 · Cited by 223
Hellström, P. M., Näslund, E., Edholm, T., Schmidt, P. T., Kristensen, J., Theodorsson, E., Holst, J. J., & Efendic, S. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.01079.x · Cited by 160
Amato, A., Cinci, L., Rotondo, A., Serio, R., Faussone-pellegrini, M. S., Vannucchi, M. G., & Mulè, F. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01476.x · Cited by 124 · cited 1×
“hypothesis is supported by the observation that GLP-1 acts in the enteric nervous system by decreasing the excitatory cholinergic neurotransmission through presynaptic GLP-1 receptors that modulate nitric oxide release (1) or by increasing sympathetic activity (5).”
BackgroundBharucha, A. E., Charkoudian, N., Andrews, C. N., Camilleri, M., Sletten, D., Zinsmeister, A. R., & Low, P. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2008 · Cited by 98 · cited 1×
“hypothesis is supported by the observation that GLP-1 acts in the enteric nervous system by decreasing the excitatory cholinergic neurotransmission through presynaptic GLP-1 receptors that modulate nitric oxide release (1) or by increasing sympathetic activity (5).”
BackgroundSelf-citation
Cited by
Fukui, H., Xu, X., & Miwa, H. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18071 · Cited by 128
Thazhath, S. S., Marathe, C. S., Wu, T., Chang, J., Khoo, J., Kuo, P., Checklin, H. L., Bound, M. J., Rigda, R. S., Crouch, B., et al. (2016) · Diabetes · doi:10.2337/db15-0893 · Cited by 83
“That GLP-1 receptor agonists are associated with diarrhea in some patients may seem at odds with our observations but could be due to acceleration of colonic transit, which was observed independently of any effect on small intestinal motility with the GLP-1 receptor agonist ROSE-010 (21).”
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
“5%) [33,34] Endocrine effects Fasting insulin secretion Absent to minor increase* Strong increase* [31,35–37] Postprandial insulin secretion Reduction† Modest increase [32,38] Fasting glucagon secretion Reduction Reduction [31,32,39] Postprandial glucagon secretion Reduction Reduction [32,39] Gastrointestinal effects…”
BackgroundJalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Langmach Wegeberg, A., Hansen, C. S., Farmer, A. D., Karmisholt, J. S., Drewes, A. M., Jakobsen, P. E., Brock, B., & Brock, C. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620925968 · Cited by 28
Metadata
- Authors
- Camilleri, M., Vazquez-Roque, M., Iturrino, J., Boldingh, A., Burton, D., McKinzie, S., Wong, B. S., Rao, A. S., Kenny, E., Månsson, M., & Zinsmeister, A. R.
- Venue
- American Journal of Physiology-Gastrointestinal and Liver Physiology
- Publisher
- American Physiological Society
- Published
- 2012-07-01
- Volume
- 303
- Issue
- 1
- Pages
- G120-G128
- ISSN
- 0193-1857 (ISSN-L)
- 1522-1547
- OpenAlex
- W2119427815
- Cited by
- 50
- References
- 11
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.